Dasatinib
Autosomal Dominant Parkinson Disease 1
Explore 7 assets in Autosomal Dominant Parkinson Disease 1 →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The Affiliated Hospital of Qingdao University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04284202CT.gov PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Autosomal Dominant Parkinson Disease 1
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dasatinib (this asset) | The Affiliated Hospital of Qingdao University | P2 | CCC · 53 |
| Lenvatinib | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC |
| f520 | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC |
| Ruxoprubart | Shanghai Pulmonary Hospital, Shanghai, China | P2 | CCC |
| Tuvonralimab | Anhui Provincial Hospital | P2 | CCC |
| Carboplatin | Shandong New Time Pharmaceutical Co., LTD | P2 | CCC |
| pd-1 knockout engineered t cells | Ruijin Hospital | P1 | CC |
| pd1-til | Ruijin Hospital | P1 | CC |
Other indications for Dasatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 68 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dasatinib in Autosomal Dominant Parkinson Disease 1. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dasatinib-autosomal-dominant-parkinson-disease-1
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →